Predicine cfWES

Liquid biopsy exome sequencing

• Genome-wide molecular insights

• Workflow flexibility

• Combines breadth and depth

• Designed for biopharma clinical trials 

Flexible workflow

Available in RUO and CLIA-validated assay

Insights into genome-wide variation

From a single sample, we provide low-pass whole genome sequencing (LP-WGS) data combined with broader coverage using WES and/or in-depth profiling using PredicineCARE™ or PredicineATLAS™ focused pan cancer panels, based on tumor fraction from the sample.

LPWGS_Predicine

Sample types

Whole blood
Plasma
cfDNA

Sample requirements

5-10ml whole blood
4-6ml plasma 
5-30ng cfDNA

Turnaround time

LP-WGS: 2 weeks
Panel: 3 weeks
WES: 4 weeks

Features and benefits

High Sensitivity Predicine

Genome-wide insights

Combined breadth and depth

Workflow flexibility

Low Input of Predicine Assays

Multiple approaches from a single sample

PILOT PROGRAM

We offer pilot program grants to select biopharma and academic partners to empower translational research and clinical studies. To initiate a study, contact us via the form below.

Contact us

If you have any questions or need assistance, complete this form and we will respond within 24 hours.

SEE OTHER TESTS